drugset / Trial / NCT00803023

Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia

NCT00803023

Phase 3 Completed 129 enrolled Jazz Pharmaceuticals
RandomizedSingle-groupSingle-blindTreatment

Summary

To compare the safety and tolerability of sodium oxybate given as a combination of an oral solution and oral tablets for 4 weeks in subjects with fibromyalgia (FM).

Timeline

Start
2010-03
Primary completion
2010-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Oxybate Unknown 4.5 g Oral
Subject Sodium Oxybate Unknown 6 g Oral

Indications